JAK1 inhibitors: Transforming autoimmune and inflammatory disease treatments, with promising future developments.

IL-17A inhibitors are a class of drugs that target the cytokine IL-17A, playing a crucial role in treating inflammation and autoimmune diseases.

IRAK4 inhibitors: Pioneering immune response regulation and promising future in combating hematologic malignancies.

JAK2 inhibitors: Revolutionizing treatments for hematological disorders with a promising future.

The KRAS mutation, as a significant driving factor for non-small cell lung cancer, has long been a challenging type of mutation. However, the recent development and clinical application of various KRAS inhibitors have brought us new hope.

IL-23 inhibitors are a class of drugs that target the cytokine IL-23, playing a crucial role in treating inflammation and autoimmune diseases.

The LAG-3 molecule can negatively requlate T cells and plays an important role in maintaining thestability of the immune system and promoting tumor immune escape. As one of the new targets, LAG-3has great potential in tumor immunotherapy.

The analysis of the target COX reveals a competitive landscape with several companies making progress in the development of COX inhibitors.

The development of inhibitors around the entire CDK family has become an important branch of drug development in the field of oncology in recent years.

Inhibiting the downstream ERK can block cell signal transduction, and ERK inhibitors can overcome tumor cells' resistance to upstream target inhibitors. This gives them broader application prospects in clinical settings.

The application of DPP-4 inhibitors brings new hope to the treatment of Type 2 Diabetes.

The development of dihydrofolate reductase inhibitors has always been challenging. dihydrofolate reductase inhibitors have therapeutic applications in cancer, malaria, and protozoan infections.